Related references
Note: Only part of the references are listed.Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis
Won-Mook Choi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients
Qi Huang et al.
HEPATOLOGY (2021)
TheCCCTC-binding factorCTCFrepresses hepatitis B virus enhancer I and regulates viral transcription
Valentina D'Arienzo et al.
CELLULAR MICROBIOLOGY (2021)
Hepatitis B virus cccDNA is formed through distinct repair processes of each strand
Lei Wei et al.
NATURE COMMUNICATIONS (2021)
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries
Jin-Lin Hou et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B
Yao-Chun Hsu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Review article: clinical pharmacology of current and investigational hepatitis B virus therapies
Elise J. Smolders et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Discovery of a novel sodium taurocholate cotransporting polypeptide (NTCP) inhibitor: Design, synthesis, and anti-proliferative activities
Honggang Xiang et al.
CHINESE CHEMICAL LETTERS (2020)
No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir
Hyunwoo Oh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Strategies to eliminate HBV infection: an update
Lydia Tang et al.
FUTURE VIROLOGY (2020)
Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis
Min Li et al.
HEPATOLOGY INTERNATIONAL (2020)
Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi
Ian Baudi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Amide-containing α-hydroxytropolones as inhibitors of hepatitis B virus replication
Qilan Li et al.
ANTIVIRAL RESEARCH (2020)
Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis
Charline Herrscher et al.
CELLULAR MICROBIOLOGY (2020)
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection
Fabien Zoulim et al.
GASTROENTEROLOGY (2020)
Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection
Zhongji Meng et al.
FRONTIERS IN IMMUNOLOGY (2020)
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B
Richard L. Mackman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Molecular, Evolutionary, and Structural Analysis of the Terminal Protein Domain of Hepatitis B Virus Polymerase, a Potential Drug Target
Timothy S. Buhlig et al.
VIRUSES-BASEL (2020)
Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B
Sayeh Ezzikouri et al.
VACCINES (2020)
HBV replication inhibitors
Claire Pierra Rouviere et al.
ANTIVIRAL RESEARCH (2020)
Mechanisms of HBV immune evasion
Adrian Kuipery et al.
ANTIVIRAL RESEARCH (2020)
Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential
Yuchen Xia et al.
ANTIVIRAL RESEARCH (2020)
Have the Starting Lineup of Five for Hepatitis B Virus Covalently Closed Circular DNA Synthesis Been Identified?
Qiong Zhao et al.
HEPATOLOGY (2020)
Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants
Keith C. K. Lau et al.
FRONTIERS IN MICROBIOLOGY (2020)
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Fathema Uddin et al.
FRONTIERS IN ONCOLOGY (2020)
Novel biomarkers for the management of chronic hepatitis B
Takako Inoue et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2020)
Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731
Qi Huang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Hepatitis B virus biology and life cycle
Senko Tsukuda et al.
ANTIVIRAL RESEARCH (2020)
3,7-Dihydroxytropolones Inhibit Initiation of Hepatitis B Virus Minus-Strand DNA Synthesis
Ellen Bak et al.
MOLECULES (2020)
IFN-alpha confers epigenetic regulation of HBV cccDNA minichromosome by modulating GCN5-mediated succinylation of histone H3K79 to clear HBV cccDNA
Ying Yuan et al.
CLINICAL EPIGENETICS (2020)
Selective hepatitis B and D virus entry inhibitors from the group of pentacyclic lupane-type betulin-derived triterpenoids
Michael Kirstgen et al.
SCIENTIFIC REPORTS (2020)
Advances in hepatitis B therapeutics
Vicente Soriano et al.
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE (2020)
Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H
John E. Tavis et al.
ACS INFECTIOUS DISEASES (2019)
Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes
Jan-Hendrik Bockmann et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives
Li Yang et al.
ACS INFECTIOUS DISEASES (2019)
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentrereal- world cohort
Bernhard Scheiner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors
Tiffany C. Edwards et al.
ANTIVIRAL RESEARCH (2019)
The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis
Zeyu Zhang et al.
BMC CANCER (2019)
Drugs in the Pipeline for HBV
Uri Lopatin
CLINICS IN LIVER DISEASE (2019)
Shedding light on RNaseH: a promising target for hepatitis B virus (HBV)
Tiffany C. Edwards et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral JNJ-64794964, a toll-like receptor-7 agonist, in healthy adults
Ed Gane et al.
JOURNAL OF HEPATOLOGY (2019)
A global scientific strategy to cure hepatitis B
Peter A. Revill et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus
Enzo Tramontano et al.
ANTIVIRAL RESEARCH (2019)
Mapping the Interactions of HBV cccDNA with Host Factors
Nur K. Mohd-Ismail et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Therapeutic strategies for hepatitis B virus infection: towards a cure
Gregory C. Fanning et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection
Adam J. Gehring et al.
GASTROENTEROLOGY (2019)
Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood
Anna L. McNaughton et al.
GASTROENTEROLOGY (2019)
Concept of Viral Inhibitors via NTCP
Kento Fukano et al.
SEMINARS IN LIVER DISEASE (2019)
Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes
Kento Fukano et al.
FRONTIERS IN MICROBIOLOGY (2019)
Divergent synthesis of a thiolate-based α-hydroxytropolone library with a dynamic bioactivity profile
Nana B. Agyemang et al.
RSC ADVANCES (2019)
Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus
Dmitry Kostyushev et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B
G. L. -H. Wong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation
Nagraj Mani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice
Kelly R. Long et al.
ANTIVIRAL RESEARCH (2018)
A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction
Wakana Saso et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections
Keye Du et al.
EXPERT OPINION ON DRUG DISCOVERY (2018)
A research agenda for curing chronic hepatitis B virus infection
Harvey Alter et al.
HEPATOLOGY (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
Harry L. A. Janssen et al.
JOURNAL OF HEPATOLOGY (2018)
2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus
Werner Embrechts et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment
K. Agarwal et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles
Thomas Tu et al.
JOURNAL OF VIROLOGY (2018)
Towards HBV curative therapies
Raymond F. Schinazi et al.
LIVER INTERNATIONAL (2018)
Amidation strategy for final-step α-hydroxytropolone diversification
Alex J. Berkowitz et al.
TETRAHEDRON LETTERS (2018)
Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes
Julie Lucifora et al.
SCIENTIFIC REPORTS (2018)
Control of viral transcripts as a concept for future HBV therapies
Christoph Seeger
CURRENT OPINION IN VIROLOGY (2018)
Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B
Aleksei Suslov et al.
CURRENT OPINION IN VIROLOGY (2018)
Hepatitis B virus infection
Man-Fung Yuen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection
Loghman Salimzadeh et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Circulating and intrahepatic antiviral B cells are defective in hepatitis B
Alice R. Burton et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
Aoran Luo et al.
VIROLOGY JOURNAL (2018)
Viral Biomarkers in Chronic HBeAg Negative HBV Infection
Emilia Hadziyannis et al.
GENES (2018)
Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action
Xingchun Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B
Kaitao Zhao et al.
EMERGING MICROBES & INFECTIONS (2018)
Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B
Zhiyong Ma et al.
VACCINES (2018)
De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry
Toby Passioura et al.
CELL CHEMICAL BIOLOGY (2018)
Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro
Antje Blank et al.
ANTIVIRAL THERAPY (2018)
Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors
Elena Lomonosova et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B
Julianne Bayliss et al.
GUT (2017)
No detectable resistance to tenofovir disoproxil fumarate in HBeAg plus and HBeAg- patients with chronic hepatitis B after 8years of treatment
Y. Liu et al.
JOURNAL OF VIRAL HEPATITIS (2017)
A New Class of Hepatitis B and D Virus Entry Inhibitors, Proanthocyanidin and Its Analogs, That Directly Act on the Viral Large Surface Proteins
Senko Tsukuda et al.
HEPATOLOGY (2017)
Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread
P. Karayiannis
HEPATOLOGY INTERNATIONAL (2017)
Hepatitis B cure: From discovery to regulatory approval
Anna S. Lok et al.
JOURNAL OF HEPATOLOGY (2017)
Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity
Satomi Shimura et al.
JOURNAL OF HEPATOLOGY (2017)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection
Yameng Pei et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Construction and Characterization of an Anti-Hepatitis B Virus preS1 Humanized Antibody that Binds to the Essential Receptor Binding Site
Jimin Wi et al.
JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks
Manasa Suresh et al.
PLOS ONE (2017)
Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application
Jianming Hu et al.
VIRUSES-BASEL (2017)
Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6
Christine M. Livingston et al.
VIRUSES-BASEL (2017)
Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP
Joanne M. Donkers et al.
SCIENTIFIC REPORTS (2017)
Novel viral and host targets to cure hepatitis B
Chunkyu Ko et al.
CURRENT OPINION IN VIROLOGY (2017)
A potent human neutralizing antibody Fc-dependently reduces established HBV infections
Dan Li et al.
ELIFE (2017)
Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H
Elena Lomonosova et al.
ANTIVIRAL RESEARCH (2017)
Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus
Jan Martin Berke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles
Tiffany C. Edwards et al.
ANTIVIRAL RESEARCH (2017)
Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants
Chih-Lin Lin et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2017)
Alpha-interferon treatment in hepatitis B
Aaron Shu Jeng Woo et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Safety of antisense oligonucleotide and siRNA-based therapeutics
Xuan Chi et al.
DRUG DISCOVERY TODAY (2017)
Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen
Tian-Ying Zhang et al.
GUT (2016)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S. K. Sarin et al.
HEPATOLOGY INTERNATIONAL (2016)
Hepatitis B: 50years after the discovery of Australia antigen
A. Suk-Fong Lok
JOURNAL OF VIRAL HEPATITIS (2016)
Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors
Juan Antonio Villa et al.
ANTIVIRAL RESEARCH (2016)
Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors
Gaofeng Lu et al.
ANTIVIRAL RESEARCH (2016)
A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B
P. Uhl et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2016)
Hepatitis B virus X protein crosses out Smc5/6 complex to maintain covalently closed circular DNA transcription
Bidisha Mitra et al.
HEPATOLOGY (2016)
Viral life cycle of hepatitis B virus: Host factors and druggable targets
Kenichi Morikawa et al.
HEPATOLOGY RESEARCH (2016)
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides
Gaetan Billioud et al.
JOURNAL OF HEPATOLOGY (2016)
First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B
Antje Blank et al.
JOURNAL OF HEPATOLOGY (2016)
Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus
David McGowan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus
Abdullah Ely et al.
MOLECULAR THERAPY (2016)
Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA
Christoph Seeger et al.
MOLECULAR THERAPY (2016)
Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor
Adrien Decorsiere et al.
NATURE (2016)
Global strategies are required to cure and eliminate HBV infection
Peter Revill et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis
Xiaolu Wu et al.
VIROLOGY JOURNAL (2016)
Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication
Christopher M. Murphy et al.
CELL REPORTS (2016)
Hepatitis B Virus X and Regulation of Viral Gene Expression
Betty L. Slagle et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Current treatments for chronic hepatitis B virus infections
Fabien Zoulim et al.
CURRENT OPINION IN VIROLOGY (2016)
Association of Hepatitis B Virus Covalently Closed Circular DNA and Human APOBEC3B in Hepatitis B Virus-Related Hepatocellular Carcinoma
Xuan Luo et al.
PLOS ONE (2016)
Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B
Kyle E. Korolowicz et al.
PLOS ONE (2016)
Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide
Xiaoli Ye et al.
SCIENTIFIC REPORTS (2016)
Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development
Daniel N. Clark et al.
ANTIVIRAL RESEARCH (2015)
The hepatitis B virus ribonuclease H as a drug target
John E. Tavis et al.
ANTIVIRAL RESEARCH (2015)
Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+-dependent taurocholate cotransporting polypeptide activity
Xue-jun Wang et al.
ANTIVIRAL RESEARCH (2015)
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent
Robert G. Gish et al.
ANTIVIRAL RESEARCH (2015)
Isolation and structure of vanitaracin A, a novel anti-hepatitis B virus compound from Talaromyces sp.
Hiroki Matsunaga et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
Marawan Ahmed et al.
DRUG DISCOVERY TODAY (2015)
Unveiling the roles of HBV polymerase for new antiviral strategies
Daniel N. Clark et al.
FUTURE VIROLOGY (2015)
Different patterns of codon usage in the overlapping polymerase and surface genes of hepatitis B virus suggest a de novo origin by modular evolution
Angelo Pavesi
JOURNAL OF GENERAL VIROLOGY (2015)
A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide
Manabu Kaneko et al.
JOURNAL OF VIROLOGY (2015)
Molecular biology of hepatitis B virus infection
Christoph Seeger et al.
VIROLOGY (2015)
Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study
Ming-Hua Su et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Hydroxylated Tropolones Inhibit Hepatitis B Virus Replication by Blocking Viral Ribonuclease H Activity
Gaofeng Lu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair?
Xiuji Cui et al.
PLOS ONE (2015)
(-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes
Hsiu-Chen Huang et al.
ANTIVIRAL RESEARCH (2014)
Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity
Catherine W. Cai et al.
ANTIVIRAL RESEARCH (2014)
Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP
Masashi Iwamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study
M-C. Tsai et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
The roles of hepatitis B virus-encoded X protein in virus replication and the pathogenesis of chronic liver disease
Mark A. Feitelson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP)
Koichi Watashi et al.
HEPATOLOGY (2014)
Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor
Shirin Nkongolo et al.
JOURNAL OF HEPATOLOGY (2014)
Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidation
F. Cao et al.
JOURNAL OF VIRAL HEPATITIS (2014)
Sirtuin 1 Regulates Hepatitis B Virus Transcription and Replication by Targeting Transcription Factor AP-1
Ji-Hua Ren et al.
JOURNAL OF VIROLOGY (2014)
Comparative Analysis of Hepatitis B Virus Polymerase Sequences Required for Viral RNA Binding, RNA Packaging, and Protein Priming
Scott A. Jones et al.
JOURNAL OF VIROLOGY (2014)
Hepatitis B virus infection
Christian Trepo et al.
LANCET (2014)
An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases
Jieliang Chen et al.
MOLECULAR THERAPY (2014)
A brief history of hepatitis milestones
Christian Trepo
LIVER INTERNATIONAL (2014)
Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses
Christian Koeniger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Julie Lucifora et al.
SCIENCE (2014)
Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection
Jia Liu et al.
PLOS PATHOGENS (2014)
Preclinical Characterization of GLS4, an Inhibitor of Hepatitis B Virus Core Particle Assembly
Guoyi Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity
Yuan Hu et al.
ANTIVIRAL RESEARCH (2013)
Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes
Julie Lucifora et al.
ANTIVIRAL RESEARCH (2013)
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus
Tassilo Volz et al.
JOURNAL OF HEPATOLOGY (2013)
Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?
Jung Hyun Kwon et al.
JOURNAL OF MEDICAL VIROLOGY (2013)
Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis
Paul A. Roethle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The Molecular Virology of Hepatitis B Virus
Dieter Glebe et al.
SEMINARS IN LIVER DISEASE (2013)
The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes
John E. Tavis et al.
PLOS PATHOGENS (2013)
Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention
Scott A. Jones et al.
EMERGING MICROBES & INFECTIONS (2013)
Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation
Dawei Cai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome
Laura Belloni et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus
Huan Yan et al.
ELIFE (2012)
Molecular Biology of the Hepatitis B Virus for Clinicians
Sibnarayan Datta et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2012)
Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
V. Rijckborst et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
HBV life cycle and novel drug targets
Daniel Grimm et al.
HEPATOLOGY INTERNATIONAL (2011)
Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection
Julie Lucifora et al.
JOURNAL OF HEPATOLOGY (2011)
Hepatitis B therapy
Hellan Kwon et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
The Expression of PD-1 Ligands and Their Involvement in Regulation of T Cell Functions in Acute and Chronic Woodchuck Hepatitis Virus Infection
Ejuan Zhang et al.
PLOS ONE (2011)
Molecular genetics of HBV infection
Stephen Locarnini et al.
ANTIVIRAL THERAPY (2010)
Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B
Paola Fisicaro et al.
GASTROENTEROLOGY (2010)
Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells
Avidan U. Neumann et al.
HEPATOLOGY (2010)
Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease
Jong Ryul Eun et al.
JOURNAL OF HEPATOLOGY (2010)
Control of hepatitis B virus at the level of transcription
M. Quasdorff et al.
JOURNAL OF VIRAL HEPATITIS (2010)
Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction
Andreas Schulze et al.
JOURNAL OF VIROLOGY (2010)
Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAs
Thomas J. Cradick et al.
MOLECULAR THERAPY (2010)
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun-Fan Liaw et al.
GASTROENTEROLOGY (2009)
Bile acid transporters
Paul A. Dawson et al.
JOURNAL OF LIPID RESEARCH (2009)
An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription
Matthew P. Badtke et al.
VIROLOGY (2009)
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein
Joerg Petersen et al.
NATURE BIOTECHNOLOGY (2008)
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial
Jinlin Hou et al.
HEPATOLOGY (2008)
Telbivudine versus lamivudine in patients with chronic hepatitis B
Ching-Lung Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Native hepatitis B virions and capsids visualized by electron cryornicroscopy
Kelly A. Dryden et al.
MOLECULAR CELL (2006)
Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release
Marcin Nowotny et al.
EMBO JOURNAL (2006)
Hepatitis B virus reverse transcriptase and ε RNA sequences required for specific interaction in vitro
JM Hu et al.
JOURNAL OF VIROLOGY (2006)
Pathogen recognition and innate immunity
S Akira et al.
CELL (2006)
The immune response during hepatitis B virus infection
Antonio Bertoletti et al.
JOURNAL OF GENERAL VIROLOGY (2006)
Crystal structures of RNase H bound to an RNA/DNA hybrid: Substrate specificity and metal-dependent catalysis
M Nowotny et al.
CELL (2005)
Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes
D Glebe et al.
GASTROENTEROLOGY (2005)
Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein
P Gripon et al.
JOURNAL OF VIROLOGY (2005)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
B7-H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes
HD Dong et al.
IMMUNITY (2004)
In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees
HJ Hong et al.
VIROLOGY (2004)
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
B Werle-Lapostolle et al.
GASTROENTEROLOGY (2004)
Regulatory elements of hepatitis B virus transcription
N Moolla et al.
JOURNAL OF VIRAL HEPATITIS (2002)
Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties
E Galun et al.
HEPATOLOGY (2002)
Share Paper
